Sittner & Nelson’s Oncolytics Biotech ONCY Stock Holding History

Sittner & Nelson’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,000	Closed	-$1.22K	–	510
2023 Q1	$1.22K	Hold	1,000	–	–	﹤0.01%	461
2022 Q4	$1.64K	Hold	1,000	–	–	﹤0.01%	430
2022 Q3	$1K	Hold	1,000	–	–	﹤0.01%	435
2022 Q2	$1K	Hold	1,000	–	–	﹤0.01%	461
2022 Q1	$2K	Hold	1,000	–	–	﹤0.01%	420
2021 Q4	$1K	Hold	1,000	–	–	﹤0.01%	423
2021 Q3	$2K	Hold	1,000	–	–	﹤0.01%	384
2021 Q2	$3K	Hold	1,000	–	–	﹤0.01%	355
2021 Q1	$4K	Hold	1,000	–	–	﹤0.01%	345
2020 Q4	$2K	Buy	+1,000	New	+$2.4K	﹤0.01%	389

Other funds holding ONCY

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

NDSI

Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

Sittner & Nelson's ONCY Position: Q2 2023 in Review

Sittner & Nelson sold out of Oncolytics Biotech (ONCY) in Q2 2023, closing a stake of 1,000 shares — an estimated $1.22K sold.

Sittner & Nelson first reported a position in ONCY in Q4 2020 and held it in 10 quarters. The position peaked at $4K in Q1 2021. 32 funds tracked by Wall St. Rank hold ONCY as of Q2 2023.

Sittner & Nelson reported no remaining Oncolytics Biotech position as of Q2 2023 after selling out during the quarter.
Sittner & Nelson sold 1,000 Oncolytics Biotech shares in Q2 2023, an estimated $1.22K.
Sittner & Nelson first reported a position in Oncolytics Biotech in Q4 2020 and held it in 10 quarters.
Sittner & Nelson's Oncolytics Biotech position peaked at $4K in Q1 2021.
32 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2023.

Based on Sittner & Nelson's 13F filing for Q2 2023, filed 14 Aug 2023.